Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting report provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020.